This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

For patients with asymptomatic severe aortic stenosis, transcatheter aortic valve replacement was superior to clinical ...

Find out why staging TAVI and PCI lowers risk in complex heart cases - read the latest insights from the ASCoP registry.

Researchers have developed cutting-edge MRI technology to diagnose a common heart problem more quickly and accurately than ever before. Aortic stenosis is a progressive and potentially fatal condition ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

University of East Anglia scientists have developed cutting-edge MRI technology to diagnose a common heart problem more quickly and accurately than ever before.

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

The U.S. Food and Drug Administration has approved the SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) ...